138.23USD-3.02%Mkt Cap: 6.74B USDP/E: —Last update: 2026-05-22
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolis…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap6.74B USD
Enterprise Value6.89B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-177.04M USD
Revenue/Share—
Last Price138.23 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees155
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)192.61
PEG—
EV/EBITDA-36.95
EV/Revenue—
P/S—
P/B128.75
EPS (TTM)-3.90
EPS (Forward)0.74
52W Range
10.2691% of range151.02
52W High151.02 USD
52W Low10.26 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-176.06%
ROA-37.95%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-153.28M USD
CapEx (TTM)249.00K USD
FCF Margin—
FCF Yield-1.64%
Net Debt-63.62M USD
Net Debt/EBITDA0.34
Balance Sheet
Debt/Equity3.20
Current Ratio12.31
Quick Ratio11.65
Book Value/Sh1.107 USD
Cash/Share7.937 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)169.00 USD
Target Range157.00 USD – 189.00 USD
# Analysts11
Ownership
Shares Out.48.77M
Float26.81M
Insiders10.01%
Institutions101.23%
Short Interest
Short Ratio12.1d
Short % Float27.87%
Short % Out.18.47%
Shares Short8.93M
Short (prev mo.)8.80M
Technical
SMA 50121.41 (+13.9%)
SMA 20092.36 (+49.7%)
Beta0.09
S&P 52W Chg28.31%
Avg Vol (30d)1.08M
Avg Vol (10d)1.07M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—